March 23, 2026 – Abbisko Therapeutics (HKEX Code: 02256) today announced that six preclinical study updates from its proprietary pipeline have been selected for poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

The AACR Annual Meeting is one of the most influential academic conferences in the global cancer research community. This year's conference will be held from April 17 to 22, 2026, at the San Diego Convention Center in California, USA.

Abbisko Therapeutics will present the following updates at the AACR Annual Meeting:

Title: Discovery of ABK-CDK4, a selective and brain-penetrant CDK4 inhibitor

Time: April 20, 2026, 9:00 AM - 12:00 PM (PDT)

Location: Section 20, Board#13

Abstract Number: 1905

Title: Synergistic antitumor activity of the MTA-cooperative PRMT5 inhibitor ABSK131 in combination with multiple therapeutic agents in diverse cancer models

Time:April 21, 2026, 9:00 AM - 12:00 PM (PDT)

Location: Section14, Board#23

Abstract Number: 4504

Title: Circulating tumor DNA (ctDNA)-based profiling of acquired resistance to the fibroblast growth factor receptor (FGFR)2/3 inhibitor lavengratinib (ABSK061) in patient(pt)s with advanced solid tumors

Time: April 21, 2026, 9:00 AM - 12:00 PM (PDT)

Location: Section 45, Board#14

Abstract Number: 5319

Title: Discovery and characterization of ABK-EGFR-1, a 4th generation EGFR C797S Inhibitor with excellent selectivity and brain penetration

Time: April 21, 2026, 2:00 PM - 5:00 PM (PDT)

Location: Section 53, Board#7

Abstract Number: LB350

Title: ABSK211, a highly potent and orally available pan-KRAS inhibitor, demonstrates robust antitumor efficacy in combination with multiple agents

Time: April 22, 2026, 9:00 AM - 12:00 PM (PDT)

Location: Section 13, Board#3

Abstract Number: 7083

Title: Preclinical characterization of ABSK211: A highly potent, orally bioavailable and selective pan-KRAS inhibitor with broad and robust activity in KRAS-driven tumors

Time: April 22, 2026, 9:00 AM - 12:00 PM (PDT)

Location: Section 13, Board#10

Abstract Number: 7090